Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
about
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart diseaseImmunohistochemical localization of phosphodiesterase 2A in multiple mammalian speciesSildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiencyBreakthrough in heart failure with preserved ejection fraction: are we there yet?Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fractionRegulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucomaSpatial control of cAMP signalling in health and diseaseTherapeutic potential of PDE modulation in treating heart diseaseExtending the translational potential of targeting NO/cGMP-regulated pathways in the CVSPhosphodiesterases and cardiac cGMP: evolving roles and controversiesCross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor TraffickingcGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac MyocytesDifferential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensorsPDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase INatriuretic peptides and the genomics of left-ventricular hypertrophy.Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin IIVolume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failureCardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension.Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2.17Beta-estradiol elevates cGMP and, via plasma membrane recruitment of protein kinase GIalpha, stimulates Ca2+ efflux from rat hepatocytes.Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.Agonist-specific compartmentation of cGMP action in myometrium.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.β-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cellsCyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes.Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation.Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arteriolesAgents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle.Heterogeneous nuclear ribonucleoprotein A1 is a novel cellular target of atrial natriuretic peptide signaling in renal epithelial cells.Assessment of cellular mechanisms contributing to cAMP compartmentalization in pulmonary microvascular endothelial cells.Defining the phosphodiesterase superfamily members in rat brain microvessels.The alpha1 isoform of soluble guanylate cyclase regulates cardiac contractility but is not required for ischemic preconditioningCardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line.
P2860
Q24323316-96DE6561-256D-469E-BD71-85DE05240796Q24337499-C9D0E83D-6E61-4D65-A9A2-5C07E02CC390Q24655371-4480BE18-99E4-42DF-BD10-31B38B469761Q26771999-F29B920B-5C02-41A2-8736-3F64D3DE791EQ26853363-8A24ED80-4926-4B9E-9EBC-EE2D68E5A360Q26861763-CE089A4D-2889-4A91-8121-BD4BB4A6FF49Q26866056-4F675FA4-789A-43BA-B250-646467F99525Q27005761-64AB14FA-C0BE-4103-B0AC-CB76C669AB63Q27021649-F5B410B2-02C1-4B34-86C3-AB8B53709CA3Q27692588-6E941B58-F67A-49BA-BE55-39AE476C08D2Q28392899-A1F518CE-D9A7-4690-9256-C5C31AA94740Q29306674-28E78E33-F7EF-4848-9D92-63AECDC863C7Q30481191-B85C287B-9BB9-45F0-8CBB-E75314B8D6DCQ30494729-2A3C7968-3A3E-45C4-9000-3914BC72DDB0Q30539041-76F9DF6D-1067-42AE-9AB3-67813EC52948Q33516818-FE4791D6-F43A-434E-B2C8-26281F5376E1Q33769656-0093C3A6-F867-486E-A0EA-9DA41FF88DBBQ33783174-6298D808-20E2-43C3-835C-986965ADCAFEQ33966155-26230AAE-9A13-488D-8395-0DD6CD331C9BQ34011572-C87211B5-97E3-407E-B3FD-1FDB4BA8340BQ34044364-158C3BF1-0A99-4DAB-957F-382CDF3FCC5AQ34094527-1FE0430B-F597-4FF2-857E-4F89D7C43F85Q34150566-9A4DA393-4F79-4992-B722-8B923C777476Q34214745-C6D466DC-B56F-40E3-97FC-09CE8017DCAAQ34244951-C4D29F88-DA65-4589-9A03-E938FBFD1E6EQ34252901-8D1F1A54-08B1-4AE1-B0EF-89F4A3A29069Q34300912-179D2E13-6D6E-4E73-93D6-1168F2CD16BDQ34456605-3B66884C-4E64-496F-94A4-8D8E8D187647Q34668034-740D39D8-6D82-4901-A765-5DC45311E3B4Q34686759-5AC82009-4048-4674-A1A7-81C7B947BD04Q35141990-337C7BB1-BC4D-4604-AD44-B1BD5C20BB8EQ35563508-B4A4359F-AB0E-4091-BC46-62A0968D7AA9Q35783161-71D5459B-F1C1-4D01-A361-1D5A1CD82B7DQ35849189-E602372F-7400-4E00-ABFA-F664CD54933EQ36015327-4655D11B-D91C-480D-ACFA-FFEE6E22E31CQ36031657-A0820BB4-9BDB-4570-AAC0-801000E4473BQ36128551-8BF8E2DA-C36B-40FB-B32D-2A092DC1AB23Q36191580-6041B59F-3955-46FD-9427-D34405846A20Q36270020-6EDDA01A-A48D-4501-8812-DDBA5EA45A5CQ36293532-80051776-B059-40E8-B8FC-85DEAA662F1C
P2860
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
@ast
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
@en
type
label
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
@ast
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
@en
prefLabel
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
@ast
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
@en
P2860
P50
P1433
P1476
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
@en
P2093
Dermot M F Cooper
P2860
P304
P356
10.1161/CIRCULATIONAHA.105.599241
P407
P577
2006-05-01T00:00:00Z